Joseph Catanzaro
Stock Analyst at Mizuho Securities
(4.58)
# 977
Out of 4,712 analysts
419
Total ratings
45.8%
Success rate
12.4%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Rated: Hold | n/a | $39.12 | - | 4 | Sep 4, 2026 | |
| SYRE Spyre Therapeutics | Rated: Hold | n/a | $90.79 | - | 5 | Sep 4, 2026 | |
| AVTX Avalo Therapeutics | Rated: Hold | n/a | $19.71 | - | 4 | Sep 4, 2026 | |
| RVMD Revolution Medicines | Rated: Hold | n/a | $207.32 | - | 18 | Sep 4, 2026 | |
| NRIX Nurix Therapeutics | Rated: Hold | n/a | $26.13 | - | 28 | Sep 4, 2026 | |
| KYMR Kymera Therapeutics | Rated: Hold | n/a | $116.47 | - | 4 | Sep 4, 2026 | |
| TNGX Tango Therapeutics | Rated: Hold | n/a | $22.70 | - | 10 | Sep 4, 2026 | |
| ERAS Erasca | Rated: Hold | n/a | $16.28 | - | 5 | Sep 4, 2026 | |
| BCAX Bicara Therapeutics | Rated: Hold | n/a | $23.71 | - | 3 | Sep 4, 2026 | |
| UPB Upstream Bio | Rated: Hold | n/a | $6.19 | - | 3 | Sep 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 → $36 | $11.69 | +207.96% | 2 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $19.10 | +161.78% | 1 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $15.90 | +13.21% | 1 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $26 | $10.71 | +142.76% | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.5 | $0.3763 | n/a | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $38 | $5.33 | n/a | 5 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3.25 | $3.65 | n/a | 15 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $53 | $108.31 | n/a | 27 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $4.75 → $4.25 | $8.29 | n/a | 15 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $1.10 | n/a | 16 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $7.5 → $6 | $8.70 | n/a | 37 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $50 → $45 | $20.03 | n/a | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $37 → $38 | $57.67 | n/a | 11 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $105 → $110 | $146.64 | n/a | 20 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 → $3 | $2.63 | n/a | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 → $15 | $11.17 | n/a | 25 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $19 | $9.44 | n/a | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $19 | $1.93 | n/a | 17 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $15 | $2.10 | n/a | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.78 | n/a | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 | $2.10 | n/a | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $1.75 | $4.39 | n/a | 9 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $2.86 | n/a | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $11.37 | n/a | 39 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $1.75 | $0.82 | n/a | 8 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.5 → $1.75 | $1.91 | n/a | 4 | Sep 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $38.13 | n/a | 4 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $1.28 | n/a | 3 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 → $4 | $39.20 | n/a | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 → $36 | $13.68 | n/a | 4 | Mar 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $1.40 | n/a | 7 | Aug 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 → $18 | $2.18 | n/a | 4 | Apr 7, 2020 |
Celldex Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $39.12
Upside: -
Spyre Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $90.79
Upside: -
Avalo Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $19.71
Upside: -
Revolution Medicines
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $207.32
Upside: -
Nurix Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $26.13
Upside: -
Kymera Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $116.47
Upside: -
Tango Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $22.70
Upside: -
Erasca
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $16.28
Upside: -
Bicara Therapeutics
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $23.71
Upside: -
Upstream Bio
Sep 4, 2026
Rated: Hold
Price Target: n/a
Current: $6.19
Upside: -
Jul 13, 2026
Reiterated: Buy
Price Target: $14 → $36
Current: $11.69
Upside: +207.96%
Apr 30, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $19.10
Upside: +161.78%
Apr 15, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $15.90
Upside: +13.21%
Mar 2, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $10.71
Upside: +142.76%
Mar 21, 2025
Maintained: Buy
Price Target: $4.5
Current: $0.3763
Upside: n/a
Mar 20, 2025
Maintained: Buy
Price Target: $36 → $38
Current: $5.33
Upside: n/a
Mar 7, 2025
Maintained: Buy
Price Target: $3.25
Current: $3.65
Upside: n/a
Mar 6, 2025
Maintained: Hold
Price Target: $53
Current: $108.31
Upside: n/a
Mar 3, 2025
Maintained: Hold
Price Target: $4.75 → $4.25
Current: $8.29
Upside: n/a
Feb 28, 2025
Maintained: Buy
Price Target: $10
Current: $1.10
Upside: n/a
Feb 28, 2025
Maintained: Hold
Price Target: $7.5 → $6
Current: $8.70
Upside: n/a
Feb 27, 2025
Maintained: Buy
Price Target: $50 → $45
Current: $20.03
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $37 → $38
Current: $57.67
Upside: n/a
Feb 12, 2025
Maintained: Buy
Price Target: $105 → $110
Current: $146.64
Upside: n/a
Jan 29, 2025
Rated: Buy
Price Target: $15 → $3
Current: $2.63
Upside: n/a
Jan 17, 2025
Maintained: Buy
Price Target: $40 → $15
Current: $11.17
Upside: n/a
Nov 6, 2024
Rated: Buy
Price Target: $19
Current: $9.44
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: $10 → $19
Current: $1.93
Upside: n/a
Oct 8, 2024
Rated: Buy
Price Target: $15
Current: $2.10
Upside: n/a
Sep 16, 2024
Reiterated: Buy
Price Target: $10 → $8
Current: $1.78
Upside: n/a
Sep 16, 2024
Rated: Buy
Price Target: $30
Current: $2.10
Upside: n/a
Aug 27, 2024
Downgraded: Hold
Price Target: $5 → $1.75
Current: $4.39
Upside: n/a
Apr 22, 2024
Initiated Coverage: Buy
Price Target: $20
Current: $2.86
Upside: n/a
Apr 8, 2024
Maintained: Buy
Price Target: $15
Current: $11.37
Upside: n/a
May 23, 2023
Downgraded: Hold
Price Target: $15 → $1.75
Current: $0.82
Upside: n/a
Sep 14, 2022
Maintained: Hold
Price Target: $1.5 → $1.75
Current: $1.91
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $6
Current: $38.13
Upside: n/a
May 31, 2022
Maintained: Buy
Price Target: $15
Current: $1.28
Upside: n/a
May 12, 2022
Maintained: Buy
Price Target: $10 → $4
Current: $39.20
Upside: n/a
Mar 9, 2022
Maintained: Buy
Price Target: $45 → $36
Current: $13.68
Upside: n/a
Aug 21, 2020
Maintained: Buy
Price Target: $15 → $17
Current: $1.40
Upside: n/a
Apr 7, 2020
Maintained: Buy
Price Target: $28 → $18
Current: $2.18
Upside: n/a